OSE Immunotherapeutics Presented New Data at AACR Annual Meeting 2017 on OSE-172 (Effi-DEM), Company’s Checkpoint Inhibitor Blocking Suppressive Myeloid Cells and Inducing Anti-tumoral Potent T Memory Response

OSE-172 (Effi-DEM) is a a first-in-class checkpoint inhibitor that blocks these suppressive cells, allowing parallel mobilization of T cells and produces dramatic anti-tumorigenic results…